Nextnet, a Propel(x) portfolio company, is advancing AI-driven biomedical discovery. The company is building an AI-powered, no-code graph analytics platform designed for biopharma and life sciences research teams.
Nextnet’s platform helps organizations uncover hidden connections between genes, proteins, and diseases. As a result, scientists can accelerate discovery and improve research productivity.
Recent Milestones at Nextnet
Over the past year, Nextnet has reached several key milestones:
- Launched the AI Knowledge Platform for Life Sciences in March 2025, expanding access for scientists and R&D teams worldwide
- Introduced two flagship modules, including Nextnet Copilot, an AI research assistant, and Nextnet Explorer, a visualization tool for knowledge graphs
- Released Free and Starter plans, opening the platform to academic labs, biotech startups, and enterprise research groups
- Gained strong engagement from leading universities and biopharma companies, with early traction in commercial evaluations for internal data integration
Why This Matters
AI and graph-based analytics are becoming a major force in healthtech. These technologies now account for nearly one-third of all healthcare investments. Nextnet is well-positioned to lead the next wave of AI-enabled biomedical research and development.
At Propel(x), we’re proud to support Nextnet’s mission to make biomedical knowledge more connected, searchable, and actionable.
Register on Propel(x) to invest in the future of innovation:
https://www.propelx.com/
